noretreat: "In the pooled analysis from the SUSTAIN and ASSURE trials (n=499), assessment of the metabolic biomarker ALP, revealed a significant reduction of -10.98% in all RVX-208 treated patients (n=331) compared to a reduction of -3.23% in placebo treated patients (n=168) (p<0.0001) at the combined time points of 24 and 26 weeks"

BDAZ: "....So I trust the statistics provided by Resverlogix since they analyzed the complete data set."

I have somewhat less confidence.  As I recall, these results are from post hoc analyses.  I would want to know how many variables were analyzed, and how many analyses were done post hoc to find this result.  I don't see any consideration of that.

I would also want to see if the results held up when looking at SUSTAIN and ASSURE separately. I thought I once saw that in a presentation a couple/few years ago, but can't remember it.